Bi-weekly dose of Johnson & Johnson's blood cancer therapy gets US FDA approval

The U.S. Food and Drug Administration has approved a bi-weekly dose of Johnson & Johnson's (JNJ.N), opens new tab blood cancer therapy Tecvayli, the drugmaker said on Tuesday.